[Federal Register: February 11, 1999 (Volume 64, Number 28)] [Notices] [Page 6913] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr11fe99-88] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated June 10, 1998, and published in the Federal Register on July 9, 1998, (63 FR 37137), Chiragene, Inc., 7 Powder Horn Drive, Warren, New Jersey 07509, made application to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed below: ------------------------------------------------------------------------ Drug Schedule ------------------------------------------------------------------------ N-Ethylamphetamine (1475).................. I 2,5-Dimethoxyamphetamine (7396)............ I 3,4-Methylenedioxyamphetamine (7400)....... I 4-Methoxyamphetamine) (7411)............... I Amphetamine (1100)......................... II Methylphenidate (1724)..................... II ------------------------------------------------------------------------ The firm plans to manufacture the listed controlled substances to supply their customers. A registered bulk manufacturer of methylphenidate filed written comments and an objection in response to the notice of application. Review of the Administrative Procedures Act's (APA) definitions of license and licensing reveals that the granting or denial of a manufacturer's registration is a licensing action, not a rulemaking. Courts have frequently distinguished between agency licensing actions and rulemaking proceedings. See, e.g., Gateway Transp. Co. v. United States, 173 F. Supp. 822, 828 (D.C. Wis. 1959); Underwater Exotics, Ltd. v. Secretary of the Interior, 1994 U.S. Dist LEXIS 2262 (1994). Courts have interpreted agency action relating to licensing as not falling within the APA's rulemaking provisions. The objector argues that Chiragene cannot prove its registration as a bulk manufacturer of methylphenidate is in the public interest, the Chiragene's registration is not required to produce an adequate and uninterrupted supply of methylphenidate, that there is sufficient competition with the present bulk manufacturers and that there would be a public interest impact on reported trends of over-prescribing, abuse and diversion of methylphenidate. The arguments of the objector were considered, however, DEA has reviewed the firm's safeguards to prevent the theft and diversion of methylphenidate and found that the firm has met the regulatory requirements and public interest factors of the Controlled Substances Act (CSA). Chiragene has been investigated by DEA to determine if the firm maintains effective controls against diversion which included, in part, inspection and testing of the firm's physical security, verification of compliance with State and local law and a review of the firm's background. The investigation has found Chiragene to be in compliance with the CSA and its implementing regulations. Under Title 21, Code of Federal Regulations, Section 1301.33(b), DEA is not required to limit the number of manufacturers solely because a smaller number is capable of producing an adequate supply provided effective controls against diversion are maintained. DEA has determined that effective controls against diversion will be maintained by Chiragene. After reviewing all the evidence, DEA has determined, pursuant to 21 U.S.C., Section 823(a), that it is consistent with the public interest to grant Chiragene's application to manufacture methylphenidate and the other listed controlled substances at this time. Therefore, pursuant to 21 U.S.C., Section 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office Of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed above is granted. Dated: January 25, 1999. John H. King, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 99-3403 Filed 2-10-99; 8:45 am] BILLING CODE 4410-09-M